Global pharmacogenomics: Where is the research taking us?

References

• André, N., Banavali, S., Snihur, Y., & Pasquier, E. (2013). Has the time come for metronomics in low-income and middle-income countries? Lancet Oncology, 14, e239–e248. doi:10.1016/S1470-2045(13)70056-1
   PubMed Web of Science ®Google Scholar
• Barker, P., & Buchanan-Barker, P. (2012). First, do no harm: Confronting the myths of psychiatric drugs. Nursing Ethics, 19, 451. doi:10.1177/0969733011429017
   PubMed Web of Science ®Google Scholar
• BCC Research. (2012). Global mental health pharmaceutical industry to reach $88.3bn by 2015. Retrieved from http://bccresearch.blogspot.ca/2012/09/global-mental-health-pharmaceutical.html
   Google Scholar
• Bollyky, T. J., Cockburn, I. M., & Berndt, E. (2010). Bridging the gap: Improving clinical development and the regulatory pathways for health products for neglected diseases. Clinical Trials, 7, 719. doi:10.1177/1740774510386390
   PubMed Web of Science ®Google Scholar
• Dauda, B., & Diereckx, K. (2012). Health, human right, and health inequalities: Alternative concepts in placing health research as justice for global health. American Journal of Bioethics, 12(11), 42–44. doi:10.1080/15265161.2012.719271
   PubMed Web of Science ®Google Scholar
• Davies, J. E., Neidle, S., & Taylor, D. G. (2012). Developing and paying for medicines for orphan indications in oncology: Utilitarian regulation vs. equitable care? British Journal of Cancer, 106, 14–17. doi:10.1038/bjc.2011.544
   PubMed Web of Science ®Google Scholar
• Di Cesare, M., Khang, Y. H., Asaria, P., Blakely, T., Cowan, M. J., Farzadfar, F., … Ezzati, M. on behalf of The Lancet NCD Action Group. (2013). Inequalities in non-communicable diseases and effective responses. Lancet, 381, 585–597. doi:10.1016/S0140-6736(12)61851-0
   PubMed Web of Science ®Google Scholar
• Evans, J. P. (2007). Health care in the age of genetic medicine. JAMA, 298, 2670–2672. doi:10.1001/jama.298.22.2670
   PubMed Web of Science ®Google Scholar
• Financial Express. (2013). India's per capita monthly average income rises to Rs 5,130 in 2011–12. Retrieved from http://www.financialexpress.com/news/indias-per-capitamonthly-average-income-rises-to-rs-5130-in-201112/1067381.
   Google Scholar
• Frueh, F. L., Amur, S., Mummaneni, P., Epstein, R. S., Aubert, R. E., DeLuca, T. M., … Lesko, L. J. (2008). Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: Prevalence of related drug use. Pharmacotherapy, 28, 992–998. doi:10.1592/phco.28.8.992
   PubMed Web of Science ®Google Scholar
• Gladding, P., White, H., Voss, J., Ormiston, J., Stewart, J., Ruygrok, P., … Webster, M. (2009). Pharmacogenetic testing for Clopidogrel using the rapid INFINITI analyzer. JACC: Cardiovascular Interventions, 2, 1095–1101. doi:10.1016/j.jcin.2009.08.018
   PubMed Web of Science ®Google Scholar
• Guttmacher, A. E., & Collins, F. S. (2005). Realizing the promise of genomics in biomedical research. JAMA, 294, 1399–1402. doi:10.1001/jama.294.11.1399
   PubMed Web of Science ®Google Scholar
• Hale, V. G., Woo, K., & Lipton, H. L. (2005). Oxymoron no more: The potential of nonprofit drug companies to deliver on the promise of medicines for the developing world. Health Affairs (Millwood), 24, 1057–1063. doi:10.1377/hlthaff.24.4.1057
   PubMed Web of Science ®Google Scholar
• Hollis, A., & Pogge, T. (2008). The health impact fund: Making new medicines accessible for all. Incentives for Global Health. Retrieved from http://machif.com/wp-content/uploads/2012/11/hif_book.pdf.
   Google Scholar
• Howitt, P., Darzi, A., Yang, G. Z., Ashrafian, H., Atun, R., Barlow, J. … Wilson, E. (2012). Technologies for global health. Lancet, 380, 507–535. doi:10.1016/S0140-6736(12)61127-1
   PubMed Web of Science ®Google Scholar
• Hurst, S. (2008). Vulnerability in research and health care; Describing the elephant in the room? Bioethics, 22, 191–202. doi:10.1111/j.1467-8519.2008.00631.x
   PubMed Web of Science ®Google Scholar
• Johnson, J. A., Cavallari, L. H., Beitelshees, A. L., Lewis, J. P., Shuldiner, A. R., & Roden, D. M. (2011). Pharmacogenomics: Application to the management of cardiovascular disease. Clinical Pharmacological Therapy, 90, 519–531. doi:10.1038/clpt.2011.179
   PubMed Web of Science ®Google Scholar
• Lenfant, C. (2013). Prospects of personalized medicine in cardiovascular diseases. Metabolism Clinical and Experimental, 62, S6–S10. doi:10.1016/j.metabol.2012.08.018
   Google Scholar
• Lesko, L. J., & Zineh, I. (2010). DNA, drugs and chariots: On a decade of pharmacogenomics at the US FDA. Pharmacogenomics, 11, 507–512. doi:10.2217/pgs.10.16
   PubMed Web of Science ®Google Scholar
• Lexchin, J. (2010). One step forward, one step sideways? Expanding research capacity for neglected diseases. International Health and Human Rights, 10, 20. doi:10.1186/1472-698X-10-20
   PubMedGoogle Scholar
• Lopez-Gomez, M., Malmierca, E., de Gorgolas, M., & Casado, E. (2013). Cancer in developing countries: The next most preventable pandemic. The global problem of cancer. Critical Reviews in Oncology/Hematology, 88(1), 117–122. doi:10.1016/j.critrevonc.2013.03.011
   PubMed Web of Science ®Google Scholar
• Ma, Q., & Lu, A. Y. H. (2011). Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacological Reviews, 63, 437–459. doi:10.1124/pr.110.003533
   PubMed Web of Science ®Google Scholar
• Maher, A., & Sridhar, D. (2012). Political priority in the global fight against non-communicable diseases. Journal of Global Health, 2, 20403. doi:10.7189/jogh.02.020403
   Google Scholar
• McLeod, H. L., & Evans, W. E. (2001). Pharmacogenomics: Unlocking the human genome for better drug therapy. Annual Review of Pharmacology and Toxicology, 41, 101–121. doi:10.1146/annurev.pharmtox.41.1.101
   PubMed Web of Science ®Google Scholar
• Meckley, L. M., Gudgeon, J. M., Anderson, J. L., Williams, M. S., & Veenstra, D. L. (2010). A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacogenomics, 28(1), 61–74.
   Google Scholar
• Olivier, C., & Williams-Jones, B. (2011). Pharmacogenomic technologies: A necessary “luxury” for better global public health? Globalization and Health, 7, 30. doi:10.1186/1744-8603-7-30
   PubMedGoogle Scholar
• Olivier, C., Williams-Jones, B., Godard, B., Mikalson, B., & Ozdemir, V. (2008). Personalized medicine, bioethics and social responsibilities: Re-thinking the pharmaceutical industry to remedy inequities in patient care and international health. Current Pharmacogenomics and Personalized Medicine, 6(2), 108–120. doi:10.2174/1875692110806020108
   Google Scholar
• Pang, T. (2003). Impact of pharmacogenomics on neglected diseases of the developing world. American Journal of Pharmacogenomics, 3, 393–398. doi:10.2165/00129785-200303060-00006
   PubMedGoogle Scholar
• Pinxten, W., Denier, Y., Dooms, M., Cassiman, J. J., & Dierickx, K. (2012). A fair share for the orphans: Ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. Journal of Medical Ethics, 38, 148–153. doi:10.1136/medethics-2011-100094
   PubMed Web of Science ®Google Scholar
• Reich, M. R. (2000). The global drug gap. Science, 287, 1979–1981. doi:10.1126/science.287.5460.1979
   PubMed Web of Science ®Google Scholar
• Reynolds, G. P. (2012). The pharmacogenetics of antipsychotic treatment. In G. Gross & M. A. Geyer (Eds.), Current antipsychotics, handbook of experimental pharmacology, 212. Berlin and Heidelberg: Springer-Verlag.
   Google Scholar
• Schroeder, D., & Singer, P. (2011). Access to life-saving medicines and intellectual property rights: An ethical assessment. Cambridge Quarterly of Healthcare Ethics, 20, 279–289. doi:10.1017/S0963180110000939
   PubMed Web of Science ®Google Scholar
• Silverman, E. (2013). Herceptin pricing in India is a joke: Menon explains. Pharmalot. Retrieved from http://www.pharmalive.com/herceptin-pricing-india-joke-menon-explains.
   Google Scholar
• So, A. D., & Ruis-Esparza, Q. (2012). Technology innovation for infectious diseases in the developing world. Infectious Diseases of Poverty, 1, 2. doi:10.1186/2049-9957-1-2
   PubMed Web of Science ®Google Scholar
• The International Warfarin Pharmacogenetics Consortium. (2009). Estimation of the Warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine, 360, 753–764. doi:10.1056/NEJMoa0809329
   PubMed Web of Science ®Google Scholar
• United Nations (UN). (2013). We can end poverty 2015: Millennium development goals. Retrieved from http://www.un.org/millenniumgoals/.
   Google Scholar
• US Food and Drug Administration. (2013). Table of pharmacogenomic biomarkers in drug labels. Retrieved from http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
   Google Scholar
• Wolinsky, H. (2005). Disease mongering and drug marketing: Does the pharmaceutical industry manufacture diseases as well as drugs? EMBO Reports, 6, 612–614. doi:10.1038/sj.embor.7400476
   PubMed Web of Science ®Google Scholar
• World Economic Forum, the Harvard School of Public Health. (2011). The global economic burden of non-communicable diseases. Geneva: Author.
   Google Scholar
• World Health Organization (WHO). (2010). Mental health and development: Targeting people with mental health conditions as a vulnerable group. Geneva: Author.
   Google Scholar
• World Health Organization (WHO). (2011a). Media center factsheet: Top 10 causes of death. Retrieved from http://who.int/mediacentre/factsheets/fs310/en/.
   Google Scholar
• World Health Organization (WHO). (2011b). Model list of essential medicines. Geneva: Author.
   Google Scholar
• World Health Organization (WHO). (2013a). Media center factsheet: Cancer. Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/.
   Google Scholar
• World Health Organization (WHO). (2013b). Draft comprehensive mental health action plan 2013–2020.
   Google Scholar